Although aromatase inhibitors are used frequently in postmenopausal breast cancer patients, erythrocytosis seems to be an uncommon side effect as most of these patients have anemia either due to the cancer itself or due to treatment administered. This evidence concerns the gene CYP19A1 and anemia.